Q-omics provides the consensus-scored FRMPD3 profile across patient tissues and cancer cell-line models. FRMPD3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FRMPD3 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, FRMPD3 RNA expression shows 17,465 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where FRMPD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRMPD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRMPD3 survival associations across molecular data types. FRMPD3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRMPD3 RNA expression–survival associations across cancer types. High FRMPD3 expression shows unfavorable associations in UVM, KIRP, UCEC and KIRC, but favorable associations in SKCM and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FRMPD3 RNA expression.
This table summarizes FRMPD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FRMPD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRMPD3 shows lower tumor expression in THCA and higher tumor expression in BRCA, LUAD, PAAD, HNSC and KIRC. The THCA box plot shows higher FRMPD3 RNA expression in normal versus tumor tissue (log2 FC = −2.315, t-test p < 0.001).
This table shows molecular features associated with FRMPD3 in patient tissues and cancer cell lines. In patient samples, FRMPD3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FRMPD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
